Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.

Details

Language :

English

ISSN :

0732183X

Volume :

41

Issue :

16

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

163946171

Full Text :

https://doi.org/10.1200/JCO.22.02823